1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Xbrane Biopharma AB (publ)
  6. Summary
    XBRANE   SE0007789409

XBRANE BIOPHARMA AB (PUBL)

(XBRANE)
  Report
Delayed Nasdaq Stockholm  -  05/27 11:29:45 am EDT
83.60 SEK   +11.91%
05/05Announcement from Xbrane Biopharma's annual general meeting
AQ
05/05TRANSCRIPT : Xbrane Biopharma AB, Q1 2022 Earnings Call, May 05, 2022
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
05/20/2022 05/23/2022 05/24/2022 05/25/2022 05/27/2022 Date
79.1(c) 77.7(c) 74.4(c) 74.7(c) 83.6 Last
26 029 4 847 43 607 16 090 27 638 Volume
+0.89% -1.77% -4.25% +0.40% +11.91% Change
More quotes
Estimated financial data (e)
Sales 2021 18,7 M 1,90 M 1,90 M
Net income 2021 -225 M -22,8 M -22,8 M
Net cash position 2021 445 M 45,1 M 45,1 M
P/E ratio 2021 -7,60x
Yield 2021 -
Sales 2022 195 M 19,8 M 19,8 M
Net income 2022 -116 M -11,8 M -11,8 M
Net cash position 2022 860 M 87,1 M 87,1 M
P/E ratio 2022 -12,5x
Yield 2022 -
Capitalization 1 870 M 190 M 190 M
EV / Sales 2021 76,1x
EV / Sales 2022 5,19x
Nbr of Employees 64
Free-Float 66,3%
More Financials
Company
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well... 
More about the company
All news about XBRANE BIOPHARMA AB (PUBL)
05/05Announcement from Xbrane Biopharma's annual general meeting
AQ
05/05TRANSCRIPT : Xbrane Biopharma AB, Q1 2022 Earnings Call, May 05, 2022
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
05/05Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/02Invitation to presentation of Xbrane Biopharma's interim report January – March 2..
AQ
04/05Correction regarding notice of annual general meeting in Xbrane Biopharma
AQ
04/04Notice of annual general meeting in Xbrane Biopharma AB
AQ
03/31Xbrane Biopharma releases annual report 2021
AQ
03/09Xbrane Biopharma - Xciting and Increasingly Compelling Case
AQ
02/24TRANSCRIPT : Xbrane Biopharma AB, Q4 2021 Earnings Call, Feb 24, 2022
CI
02/24Xbrane Biopharma releases Year-end report 2021
AQ
02/24Xbrane Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2021
CI
02/23Invitation to presentation of xbrane biopharma's year-end report 2021 on february 24, 2..
AQ
02/22Invitation to presentation of Xbrane Biopharma's Year-end report 2021 on February 24, 2..
AQ
02/17Biogen And Xbrane Enter Into Worldwide Commercialization And License Agreement For Cert..
AQ
More news
News in other languages on XBRANE BIOPHARMA AB (PUBL)
05/05Xbrane Biopharma AB (publ) annonce ses résultats financiers pour le premier trimestre c..
02/24Xbrane Biopharma AB (publ) annonce ses résultats pour l'exercice clos le 31 décembre 20..
02/15Xbrane Biopharma AB (Publ) annonce des résultats positifs de l'étude pivot de phase III..
02/07Biogen Inc. et Xbrane Biopharma AB (publ) annoncent un accord de commercialisation et d..
2017Xbrane Biopharma AB (Publ) réaffirme ses prévisions de ventes pour l'année 2017
More news
Chart XBRANE BIOPHARMA AB (PUBL)
Duration : Period :
Xbrane Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XBRANE BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 74,70 SEK
Average target price 235,00 SEK
Spread / Average Target 215%
EPS Revisions
Managers and Directors
Martin ┼mark Chief Executive Officer
Anette Lindqvist Chief Financial Officer & Head-Investor Relations
Anders Lennart Tullgren Chairman
David Vikstr÷m Chief Technology Officer
Siavash Bashiri Chief Operating Officer & Head-Biosimilars
Sector and Competitors
1st jan.Capi. (M$)
XBRANE BIOPHARMA AB (PUBL)-28.72%189
MODERNA, INC.-48.48%52 047
LONZA GROUP AG-28.07%42 228
IQVIA HOLDINGS INC.-27.93%38 488
SEAGEN INC.-11.73%25 121
ICON PUBLIC LIMITED COMPANY-31.56%17 232